Assessing the prognostic features of a pain classification system in advanced cancer patients

Arthur, Joseph; Tanco, Kimberson; Haider, Ali; Maligi, Courtney; Park, Minjeong; Liu, Diane; Bruera, Éduardo

doi:10.1007/s00520-017-3702-z

Cited by 15 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we found that, at baseline, patients with a neuropathic component of the index pain had greater pain intensity, worse performance status, worse pain interference scores, and used opioid analgesics more frequently than patients without this component. Our findings are consistent with past studies that investigated neuropathic cancer pain, which demonstrated that patients with neuropathic pain were likely to have a higher pain intensity, worse performance status, worse pain interference, worse quality of life, and more frequent analgesic use [14] , [15] , [16] . Neuropathic cancer pain is associated with a negative impact on patients’ life quality and functioning despite greater use of analgesics.…”

Section: Discussionsupporting

confidence: 92%

A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective observational study

Saitô

Tomitaka

Toya

et al. 2018

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective observational study

Saitô

Tomitaka

Toya

et al. 2018

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…The total symptom distress score (SDS) was calculated as the sum of all the ESAS scores. A higher score indicates higher symptom distress, whereas a lower score indicates less symptom distress . In a previous study, the optimal minimal clinically important difference cutoff for SDS was found to be ≥+2 points for improvement and ≤−1 point for deterioration .…”

Section: Methodsmentioning

confidence: 95%

Outcomes of a Specialized Interdisciplinary Approach for Patients with Cancer with Aberrant Opioid-Related Behavior

Arthur¹,

Edwards²,

Reddy³

et al. 2017

The Oncologist

Self Cite

View full text Add to dashboard Cite

There are currently no well-defined and evidence-based strategies to manage cancer patients on chronic opioid therapy who demonstrate aberrant opioid-related behavior. The findings of this study offer a promising starting point for the creation of a standardized strategy for clinicians and provides valuable information to guide their practice regarding these patients. The study results will also help clinicians to better understand the types and frequencies of the most common aberrant behaviors observed among patients with cancer who are receiving chronic opioid therapy. This will enhance the process of timely patient identification, management, or referral to the appropriate specialist teams.

show abstract

“…Patients who died, enrolled in hospice care, or had to transition their oncologic care outside the institution were not considered eligible for intention‐to‐treat analysis. The total symptom distress score (SDS) was calculated as the sum of all the ESAS scores 25–27 …”

Section: Methodsmentioning

confidence: 99%

Interdisciplinary intervention for the management of nonmedical opioid use among patients with cancer pain

Arthur

Edwards

et al. 2022

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Few studies have assessed interventions aimed at managing nonmedical opioid use (NMOU) behavior among patients with cancer. The authors developed the Compassionate High-Alert Team (CHAT) intervention to manage patients receiving opioids for cancer pain who demonstrate NMOU behavior. The objective of this study was to determine the change in frequency of NMOU behaviors, pain intensity, and opioid requirements among those who received the intervention. METHODS: A total of 130 patients receiving opioids for cancer pain that had documented evidence of NMOU and received the CHAT intervention were reviewed. Demographic and clinical information such as NMOU behaviors, pain scores, and morphine equivalent daily dose at baseline, 3, and 6 months post-intervention was obtained. RESULTS: NMOU behaviors significantly decreased from a median (interquartile range) of 2 (1-3) at baseline to 0 (0-1) at both 3 and 6 months post-intervention (p < .001). A total of 45 of 75 (60%) and 31 of 50 (62%) of CHAT recipients achieved complete response to the intervention at 3 and 6 months, respectively. Higher baseline number of NMOU behaviors was independently associated with patient response to the intervention (odds ratio [OR], 1.97; 95% confidence interval [CI],1.09-4.28, p = .049 at 3 months; OR, 2.5; 95% CI, 1.20-6.47, p = .03 at 6 months). The median pain score decreased from 7 at baseline to 6 at both 3 and 6 months (p = .01). Morphine equivalent daily dose did not significantly change during that same period (143 mg/day vs. 139 mg/day, p = .13). CONCLUSIONS: Most patients who received the CHAT intervention improved in their NMOU behaviors and pain intensity scores 3 and 6 months post-intervention. These preliminary findings support the efficacy of CHAT in managing patients receiving opioids for cancer pain who demonstrate NMOU behavior.

show abstract

Assessing the prognostic features of a pain classification system in advanced cancer patients

Cited by 15 publications

References 33 publications

A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective observational study

A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective observational study

Outcomes of a Specialized Interdisciplinary Approach for Patients with Cancer with Aberrant Opioid-Related Behavior

Interdisciplinary intervention for the management of nonmedical opioid use among patients with cancer pain

Contact Info

Product

Resources

About